Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Starr

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Molecular Cancer Therapeutics|July 13, 2018
Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105Yingmiao Liu, Mark D Starr, John C Brady, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|July 4, 2013
Men's experience with sexual dysfunction post-rectal cancer treatment: a qualitative studyMelinda Ball, Christian J Nelson, Elyse Shuk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance)Andrew B Nixon, Herbert Pang, Mark D Starr, et al.
Journal of Cancer Survivorship : Research and Practice|December 16, 2015
The sexual health of female rectal and anal cancer survivors: results of a pilot randomized psycho-educational intervention trialKatherine DuHamel, Tammy Schuler, Christian Nelson, et al.
Cancer Medicine|February 28, 2014
Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancerYingmiao Liu, Mark D Starr, John C Brady, et al.
Gynecologic Oncology|January 7, 2011
Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cellsDeanna Teoh, Tina A Ayeni, Jennifer M Rubatt, et al.
Carcinogenesis|September 9, 2016
TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3Rachel A Hesler, Jennifer J Huang, Mark D Starr, et al.
Transfusion Medicine (Oxford, England)|October 5, 2001
Panel Discussion. Millennium Festival of Medicine--Transfusion 2020--18 October 2000M Fogden, K Whitehorn, D Starr, et al.
Orphanet Journal of Rare Diseases|September 4, 2021
Pilot investigation of circulating angiogenic and inflammatory biomarkers associated with vascular malformationsSarah E Wetzel-Strong, Shantel Weinsheimer, Jeffrey Nelson, et al.
Cancer Chemotherapy and Pharmacology|December 21, 2014
A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumorsHope E Uronis, Jingquan Jia, Johanna C Bendell, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Molecular Cancer Therapeutics|July 13, 2018
Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105Yingmiao Liu, Mark D Starr, John C Brady, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|July 4, 2013
Men's experience with sexual dysfunction post-rectal cancer treatment: a qualitative studyMelinda Ball, Christian J Nelson, Elyse Shuk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2013
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance)Andrew B Nixon, Herbert Pang, Mark D Starr, et al.
Journal of Cancer Survivorship : Research and Practice|December 16, 2015
The sexual health of female rectal and anal cancer survivors: results of a pilot randomized psycho-educational intervention trialKatherine DuHamel, Tammy Schuler, Christian Nelson, et al.
Cancer Medicine|February 28, 2014
Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancerYingmiao Liu, Mark D Starr, John C Brady, et al.
Gynecologic Oncology|January 7, 2011
Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cellsDeanna Teoh, Tina A Ayeni, Jennifer M Rubatt, et al.
Carcinogenesis|September 9, 2016
TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3Rachel A Hesler, Jennifer J Huang, Mark D Starr, et al.
Transfusion Medicine (Oxford, England)|October 5, 2001
Panel Discussion. Millennium Festival of Medicine--Transfusion 2020--18 October 2000M Fogden, K Whitehorn, D Starr, et al.
Orphanet Journal of Rare Diseases|September 4, 2021
Pilot investigation of circulating angiogenic and inflammatory biomarkers associated with vascular malformationsSarah E Wetzel-Strong, Shantel Weinsheimer, Jeffrey Nelson, et al.
Cancer Chemotherapy and Pharmacology|December 21, 2014
A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumorsHope E Uronis, Jingquan Jia, Johanna C Bendell, et al.
Pageof 9